Welcome to the e-CCO Library!

P409 Endoscopic and histological activity is associated with non-response to biologic therapy in ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. WANN1, R. Norris1, R. Williams2, C. Basnayake1, M. Lust1, E. Wright1, M. Kamm1, W. Connell1, A. Thompson1, N. Ding1

Created: Thursday, 30 January 2020, 10:12 AM
P409: FMT induced increase in gut microbial diversity and Clostridia is associated with clinical response in patients with ulcerative colitis – results from STOP Colitis trial
Year: 2022
Source: ECCO'22
Authors: Quraishi, M.N.(1);Quince, C.(2);Hewitt, C.(3);Beggs, A.(4);Gerasimidis , K.(5);Sharma, N.(1);Hawkey, P.(6);Oo, Y.(7);Ives, N.(3);Manzoor, S.(8);Loman, N.(6);Hansen, R.(9);Hart, A.(10);Gaya, D.(11);Iqbal, T.(1);
Created: Friday, 11 February 2022, 3:52 PM
P409: Impact of biological therapy in postoperative morbidity in elective surgical resections in Crohn’s disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

P. G. Kotze*1, M. P. Saab1, B. Saab1, L. M. S. Kotze1, M. Olandoski2, L. V. Pinheiro3, C. A. R. Martinez3, M. L. S. Ayrizono3, D. O. Magro3, C. S. R. Coy3

Created: Friday, 22 February 2019, 9:49 AM
P409: Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet’s disease: Results from a real-world observational study
Year: 2018
Source: ECCO '18 Vienna
Authors:

Y. Suzuki1*, T. Hagiwara2, M. Kobayashi2, K. Morita2, T. Shimamoto2, T. Hibi3

Created: Thursday, 21 February 2019, 9:14 AM
P409: Mesalamine enemas for induction of remission in pediatric ulcerative colitis refractory to oral mesalamine: a prospective cohort study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Levine A.*1, Yerushalmi B.2, Kori M.3, Broide E.4, Mozer-Glassberg Y.5, Shaoul R.6, Kolho K.-L.7, Shteyer E.8, Shamaly H.9, Ledder O.10, Cohen S.11, Peleg S.12, Sarbagili-Shabat C.1, Focht G.10, Shachmon E.10, Boaz M.13, On A.14, Turner D.10

Created: Wednesday, 20 February 2019, 10:36 AM
P409: Non-invasive predictors of maintaining remission in patients with moderately to severely active Ulcerative Colitis treated with tofacitinib who dose-reduced from tofacitinib 10 mg twice daily to 5 mg twice daily: 6-month data from the double-blind, randomised RIVETING study
Year: 2021
Source: ECCO'21 Virtual
Authors: D’Haens, G.R.(1);Dubinsky, M.C.(2);Regueiro, M.(3);Santana, G.O.(4);Torres, J.(5);Kulisek, N.(6);Gardiner, S.(7);Mundayat, R.(7);Paulissen, J.(7);Lawendy, N.(6);Su, C.(6);Modesto, I.(7);Sandborn, W.J.(8);
Created: Wednesday, 2 June 2021, 4:12 PM
P409: Non-medical reverse switch between the originator infliximab and its biosimilar in patients with inflammatory bowel disease: clinical outcomes and therapeutic drug monitoring
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

L. Gonczi*1, A. Ilias1, K. Szanto2, Z. Kurti1, P. A. Golovics3, K. Farkas2, E. Schafer3, Z. Szepes2, B. Szalay4, A. Vincze5, T. Szamosi3, T. Molnar2, P. Lakatos6

Created: Friday, 22 February 2019, 9:41 AM
P409: Using antidepressants for refractory symptoms of Inflammatory Bowel Disease: a prospective service evaluation
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Moulton, C.(1)*;Avery, P.(2);Hart, A.(3);
Created: Friday, 14 July 2023, 11:05 AM
P410 Could the disease become ‘a friend’? The mediating role of illness acceptance on self-efficacy and quality of life of gastroenterological patients
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Rudnik1,2, G. Piotrowicz2, G. Rydzewska3,4, M. Bidzan1, E. Ozgo5

Created: Thursday, 30 January 2020, 10:12 AM
P410: Extraintestinal manifestations and quality of life in patients with ulcerative colitis: 1-year data from ICONIC
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Ghosh*1, F. Casellas2, C. O’Shea3, M. Leonard3, J. Petersson4, L. Peyrin-Biroulet5

Created: Friday, 22 February 2019, 9:41 AM
P410: Has body composition any effect on thiopurine level in IBD?
Year: 2018
Source: ECCO '18 Vienna
Authors:

Á. Milassin1*, K. Szántó1, A. Fábián1, R. Bor1, K. Farkas1, A. Bálint1, M. Rutka1, I. Földesi2, A.L. Szijártó3, Z.A. Mezei4, T. Bubán5, F. Nagy1, Z. Szepes1, T. Molnár1, K. Palatka6

Created: Thursday, 21 February 2019, 9:14 AM
P410: Long-term persistence and safety of biological drugs in patients with Inflammatory Bowel Disease. Differences between women and men: SEXEII study of ENEIDA
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Gargallo-Puyuelo, C.(1)*;Ricard, E.(2);Iborra, M.(3);Iglesias-Flores, E.(4);Vera Mendoza, I.(5);De Francisco García, R.(6);Calafat Sard, M.(7);Minguez, M.(8);Lopez- San Roman, A.(9);Taxonera, C.(10);Guardiola, J.(11);Barrio, J.(12);Laredo, V.(13);De Castro, L.(14);Gisbert, J.(15);García-Lopez, S.(16);García Planella, E.(17);Martín Arranz, D.(18);Calvet, X.(19);Merino, O.(20);Sierra, M.(21);Marquez, L.(22);Madero, L.(23);Varela, P.(24);Carpio, D.(25);Esteve, M.(26);Rivero, M.(27);Ramos , L.(28);Sicilia, B.(29);Lorente POyatos, R.(30);Marin, I.(31);Monfort, D.(32);Navarro, M.(33);VEga, P.(34);Hinojosa, J.(35);Tardillo, C.(36);García Sepulcre, M.F.(37);Barreiro, M.(38);Domenech, E.(7);Gomollón, F.(39);
Created: Friday, 14 July 2023, 11:05 AM
P410: safety of biological drugs for inflammatory bowel disease in elderly patients
Year: 2022
Source: ECCO'22
Authors: Suarez Ferrer, C.J.(1);Mesonero, F.(2);Caballol, B.(3);Ballester, M.P.(4);Baston Rey, I.(5);Castaño Garcia, A.(6);Miranda Bautista, J.(7);Saiz Chumillas, R.(8);Benitez , J.M.(9);Sanchez Delgado, L.(10);Lopez-Garcia, A.(11);Rubin de Celix, C.(12);Lopez Sanroma, A.(2);Martin-Arranz, M.D.(13);Fernández-Clotet , A.(3);Merino Murgui , V.(14);Calviño Suárez , C.(15);Florez, P.(16);Lobato matilla, M.E.(7);Sicilia, B.(17);Soto Escribano, P.(18);Maroto Martin , C.(10);Alonso Abreu, I.(19);Melcarne, L.(20);Plaza Santos, R.(21);Marques Cami, M.(22);Caballero Mateos , A.(23);Gómez Díez , C.(24);Calafat, M.(25);Alonso Galan, H.(26);Vega Villaamil , P.(27);Castro Senosiain , B.(28);Guerro Moya , A.(29);Rodriguez Diaz , C.Y.(30);Spicakova, K.(31);Manceñido Marcos, N.(32);Molina, G.(33);De Castro, L.(34);Mañosa Ciria , M.(25);Barreiro-De Acosta , M.(15);
Created: Friday, 11 February 2022, 3:52 PM
P410: Segmental endoscopic scoring improves outcome prediction in acute severe colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Raimundo Fernandes*, P. Santos, C. Moura, P. Marques da Costa, J. Rita Carvalho, C. Baldaia, A. Valente, A. Rita Gonçalves, P. Moura Santos, L. Correia, J. Velosa

Created: Friday, 22 February 2019, 9:49 AM
P410: Vedolizumab is safe and effective for IBD, but has no effect on liver biochemistry in patients with concurrent PSC
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Christensen B.*1, Micic D.2, Gibson P.R.1, Singh S.3, Bellaguarda E.2, Corsello P.4, Gaetano J.N.5, Kinnucan J.4, Rao V.L.5, Reddy S.2, Yarur A.3, Rubin D.T.5, Pekow J.5

Created: Wednesday, 20 February 2019, 10:36 AM
P410: Which patients with established Crohn's disease benefit most from the use of the Patency capsule test prior to small bowel capsule endoscopy?
Year: 2021
Source: ECCO'21 Virtual
Authors: Elosua Gonzalez, A.(1);Rullan Iriarte, M.(1);Rubio Iturria, S.(2);Rodríguez Gutiérrez, C.(2);Vicuña Arregui, M.(2);Elizalde Apesteguía, I.(2);Aznárez Barrio, M.R.(2);Juanmartiñena Fernández, J.F.(2);Nantes Castillejo, Ó.(2);Fernández-Urién, I.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P411 Faecal calprotectin is more tightly associated with endoscopic disease activity compared with other biomarkers in patients with inflammatory bowel disease under maintenance treatment with adalimumab
Year: 2020
Source:

ECCO'20 Vienna

Authors:

E. Orfanoudaki, E. Theodoraki, K. Foteinogianopoulou, A. Mantaka, I. Koutroubakis

Created: Thursday, 30 January 2020, 10:12 AM
P411: Baseline Hypertrophy of the Submucosa at intestinal ultrasound predicts Failure of Treatment in patients with ulcerative colitis
Year: 2021
Source: ECCO'21 Virtual
Authors: de Voogd, F.(1);Duijvestein, M.(1);Ponsioen, C.(1);Löwenberg, M.(1);D'Haens, G.(1);Gecse, K.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P411: Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease centre: Accessibility, resource utilisation and outcomes
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Restellini1,2*, I. Morin1, Z. Kurti3, T. Bessissow1, W. Afif1, G. Wild1, E. Seidman1, A. Bitton1, P.L. Lakatos1,3

Created: Thursday, 21 February 2019, 9:14 AM
P411: Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kurti Z.*1, Rutka M.2, Vegh Z.1, Gonczi L.1, Farkas K.2, Lovasz B.D.1, Gecse K.B.1, Golovics P.A.1, Szalay B.3, Molnar T.2, Lakatos P.L.1

Created: Wednesday, 20 February 2019, 10:36 AM